Pediatric Infection and Vaccine

  • 제20권3호
  • /
  • Pages.161-167
  • /
  • 2013
  • /
  • 2384-1079(pISSN)
  • /
  • 2384-1087(eISSN)
대한소아감염학회 (The Korean Society of Pediatric Infectious Diseases)
권호 표지

수두-대상포진 바이러스 감염으로 입원한 소아에 대한 임상 고찰

Clinical Manifestations of Hospitalized Children Due to Varicella-Zoster Virus Infection

  • 곽병옥 (서울대학교병원 소아청소년과) ;
  • 김동현 (서울대학교병원 소아청소년과) ;
  • 이환종 (서울대학교병원 소아청소년과) ;
  • 최은화 (서울대학교병원 소아청소년과)
  • Kwak, Byung Ok (Department of Pediatrics, Seoul National University Children's Hospital) ;
  • Kim, Dong Hyun (Department of Pediatrics, Seoul National University Children's Hospital) ;
  • Lee, Hoan Jong (Department of Pediatrics, Seoul National University Children's Hospital) ;
  • Choi, Eun Hwa (Department of Pediatrics, Seoul National University Children's Hospital)
  • 투고 : 2013.02.15
  • 심사 : 2013.04.16
  • 발행 : 2013.12.25
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목적: 본 연구는 단일 기관에서 수두-대상포진 바이러스 감염으로 입원한 소아 환자의 임상 경과를 알아보고자 하였다. 방법: 2009년부터 2012년까지 서울대학교 어린이병원에서 피부 병변의 수포액으로 시행한 수두-대상포진 바이러스 배양검사와 중합효소 연쇄반응검사로 수두-대상포진 바이러스 감염증이 확진된 40명의 입원환자를 대상으로 하였다. 환자들의 의무기록을 통하여 진단 시 연령 및 성별, 수두 백신 시행유무, 임상증상 및 경과, 기저질환, 치료와 합병증에 대하여 분석하였다. 결과: 대상자 중 수두 환자는 16명, 대상포진 환자는 24명이었고, 연령 중앙값은 10.5세로 생후 16일부터 19세까지 분포하였다. 기저질환이 동반된 환자는 35명(87.5%)이었고, 24명의 대상포진 환자 중 과거에 수두를 앓았던 경우가 11례에서 있었고, 재발한 대상포진은 1례에서 있었다. 20명(50%)은 이전에 수두 백신의 접종력이 있었고, 이 중 19명은 면역저하환자였다. 대부분의 환자(95%)는 정맥용 또는 경구용 항바이러스제로 치료받았고, 정맥용 항바이러스제 투여 후 치료 실패는 관찰되지 않았다. 면역저하환자에서 발열의 기간은 평균 4.4일(1-10일)로 정상 면역력을 가진 환자와 비교하였을 때 유의한 차이는 없었으나, 항바이러스제의 투여기간은 평균 12일(7-23일)로 유의하게 길었다(P=0.014). 두 명(5.0%)의 환자에서 Streptococcus pyogenes와 Klebsiella oxytoca에 의한 이차 세균 감염이 확인되었으며, 1명(2.5%)에서 폐렴이, 11명(27.5%)에서 대상포진후 신경통이 합병되었다. 결론: 수두-대상포진 바이러스 감염은 면역저하 소아에서 발생할 시에 장기간의 항바이러스제 치료가 필요하므로 이 같은 환자들을 적극적으로 치료하고, 면밀하게 관찰하는 것이 필요하다.

Purpose: This study was performed to describe the clinical manifestations of hospitalized children due to varicella-zoster virus (VZV) infection Methods: This study included 40 children who were hospitalized for varicella or herpes zoster at Seoul National University Children's Hospital, 2009-2012. Diagnosis of VZV infection was confirmed by VZV PCR or culture from vesicular fluid. Medical records were reviewed to collect clinical features and outcome, antiviral treatment, history of varicella vaccination, and underlying diseases. Results: Sixteen patients with varicella and 24 patients with herpes zoster were included. Their median age was 10.5 years (16 days-19 years). Thirty-five (87.5%) patients had underlying diseases. Among 24 patients with herpes zoster, 11 patients had previous history of varicella and 1 had herpes zoster. Twenty patients (50%) had a history of varicella vaccination, and 19 immunocompromised patients had VZV infection despite of vaccination. Most (95%) patients were treated by intravenous or oral acyclovir, and no treatment failure of intravenous acyclovir was found. The median duration of fever was 4.4 days (1-10 days), and that of antiviral treatment was 12 days (7-23 days) in immunocompromised patients. Immunocompromised patients received longer duration of antiviral treatment than imunocompetent patients (P=0.014). Eleven (27.5 %) immunocompromised patients had postherpetic neuralgia, 2 (5%) had proven co-infection by Streptococcus pyogenes and Klebsiella oxytoca, and 1 (2.5%) complicated with pneumonia. Conclusion: Immunocompromised children require longer duration of treatment and are at risk of severe complication associated with VZV infection. Early initiation of antiviral therapy and close monitoring are necessary for those in immunocompromised conditions.

키워드

참고문헌

  1. Davison AJ, Scott JE. The complete DNA sequence of varicella-zoster virus. J Gen Virol 1986;67(Pt 9):1759-816. https://doi.org/10.1099/0022-1317-67-9-1759
  2. Schmidt-Chanasit J, Sauerbrei A. Evolution and worldwide distribution of varicella-zoster virus clades. Infect Genet Evol 2011;11:1-10. https://doi.org/10.1016/j.meegid.2010.08.014
  3. Seward JF, Watson BM, Peterson CL, Mascola L, Pelosi JW, Zhang JX, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 2002;287:606-11. https://doi.org/10.1001/jama.287.5.606
  4. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974;2:1288-90.
  5. Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 2005;352:450-8. https://doi.org/10.1056/NEJMoa042271
  6. Oh SH. Update in varicella vaccination. Korean J Pediatr 2006;49:229-34. https://doi.org/10.3345/kjp.2006.49.3.229
  7. Choi EH. Varicella vaccination: worldwide status and provisional updated recommendation in Korea. Korean J Pediatr Infect Dis 2008:15;11-8.
  8. Park SJ, Song HJ, Kim CW, Lee KS. A clinical study of 72 cases of herpes zoster in children and adolescents. Korean J Dermatol 2006;44:664-8.
  9. Seo PS, Yoon NH, Park SD. A clinical study of chicken pox in adolescents and adults. Korean J Dermatol 2005;43:933-8.
  10. Lee GH, Lee SH, Lee SY, Lee JS, Whang KU. A clinical study of chickenpox in adult inpatients. Korean J Dermatol 2010;48:272-7.
  11. Park CK, Kim HO, Park CW, Lee CH. The effect of active immunization on the clinical courses of varicella. Korean J Dermatol 2008;46:1011-9.
  12. Loparev VN, Rubtcova E, Seward JF, Levin MJ, Schmid DS. DNA sequence variability in isolates recovered from patients with postvaccination rash or herpes zoster caused by Oka varicella vaccine. J Infect Dis 2007;195:502-10. https://doi.org/10.1086/510532
  13. Loparev VN, Gonzalez A, Deleon-Carnes M, Tipples G, Fickenscher H, Torfason EG, et al. Global identification of three major genotypes of varicella-zoster virus: longitudinal clustering and strategies for genotyping. J Virol 2004;78:8349-58. https://doi.org/10.1128/JVI.78.15.8349-8358.2004
  14. Carapetis JR, Russell DM, Curtis N. The burden and cost of hospitalised varicella and zoster in Australian children. Vaccine 2004;23:755-61. https://doi.org/10.1016/j.vaccine.2004.07.025
  15. Marshall HS, McIntyre P, Richmond P, Buttery JP, Royle JA, Gold MS, et al. Changes in patterns of hospitalized children with varicella and of associated varicella genotypes following introduction of varicella vaccine in Australia. Pediatr Infect Dis J 2013;32:530-7. https://doi.org/10.1097/INF.0b013e31827e92b7
  16. van Lier A, van der Maas NA, Rodenburg GD, Sanders EA, de Melker HE. Hospitalization due to varicella in the Netherlands. BMC Infect Dis 2011;11:85. https://doi.org/10.1186/1471-2334-11-85
  17. Kim SH, Lee HJ, Park SE, Oh SH, Lee SY, Choi EH. Seroprevalence rate after one dose of varicella vaccine in infants. J Infect 2010;61:66-72. https://doi.org/10.1016/j.jinf.2010.04.001
  18. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004;4:26-33. https://doi.org/10.1016/S1473-3099(03)00857-0
  19. Nagasawa K, Yamauchi Y, Tada Y, Kusaba T, Niho Y, Yoshikawa H. High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis. Ann Rheum Dis 1990;49:630-3. https://doi.org/10.1136/ard.49.8.630
  20. Morens DM, Bregman DJ, West CM, Greene MH, Mazur MH, Dolin R, et al. An outbreak of varicella-zoster virus infection among cancer patients. Ann Intern Med 1980;93:414-9. https://doi.org/10.7326/0003-4819-93-3-414
  21. Adler AL, Casper C, Boeckh M, Heath J, Zerr DM. An outbreak of varicella with likely breakthrough disease in a population of pediatric cancer patients. Infect Control Hosp Epidemiol 2008;29:866-70. https://doi.org/10.1086/590358
  22. Folatre I, Zolezzi P, Schmidt D, Marin F, Tager M. Infections caused by varicella zoster virus in children with cancer aged less than 15 years old. Rev Med Chil 2003;131:759-64.
  23. Arvin AM. Antiviral therapy for varicella and herpes zoster. Semin Pediatr Infect Dis 2002;13:12-21. https://doi.org/10.1053/spid.2002.29753
  24. Prober CG, Kirk LE, Keeney RE. Acyclovir therapy of chickenpox in immunosuppressed children--a collaborative study. J Pediatr 1982;101:622-5. https://doi.org/10.1016/S0022-3476(82)80725-7
  25. Nyerges G, Meszner Z, Gyarmati E, Kerpel-Fronius S. Acyclovir prevents dissemination of varicella in immunocompromised children. J Infect Dis 1988;157:309-13. https://doi.org/10.1093/infdis/157.2.309
  26. Novelli VM, Marshall WC, Yeo J, McKendrick GD. Acyclovir administered perorally in immunocompromised children with varicella-zoster infections. J Infect Dis 1984;149:478. https://doi.org/10.1093/infdis/149.3.478
  27. Meszner Z, Nyerges G, Bell AR. Oral acyclovir to prevent dissemination of varicella in immunocompromised children. J Infect 1993;26:9-15. https://doi.org/10.1016/0163-4453(93)96648-A
  28. Jain Y, Lodha R, Tomar S, Arya LS, Kabra SK. Oral acyclovir in varicella zoster virus infections in children with acute lymphoblastic leukemia. Indian Pediatr 2000;37:1239-41.
  29. Carcao MD, Lau RC, Gupta A, Huerter H, Koren G, King SM. Sequential use of intravenous and oral acyclovir in the therapy of varicella in immunocompromised children. Pediatr Infect Dis J 1998;17:626-31. https://doi.org/10.1097/00006454-199807000-00010
  30. Bomgaars L, Thompson P, Berg S, Serabe B, Aleksic A, Blaney S. Valacyclovir and acyclovir pharmacokinetics in immunocompromised children. Pediatr Blood Cancer 2008;51:504-8. https://doi.org/10.1002/pbc.21638
  31. Eksborg S, Pal N, Kalin M, Palm C, Soderhall S. Pharmacokinetics of acyclovir in immunocompromized children with leukopenia and mucositis after chemotherapy: can intravenous acyclovir be substituted by oral valacyclovir?Med Pediatr Oncol 2002;38:240-6. https://doi.org/10.1002/mpo.1317